TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22144722

Group type: EXPERIMENTAL
Intervention: Thermal mineral water at 38°C for three weeks, five times a week for 20 minutes a day plus magnetotherapy three times weekly.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Thermal mineral water at 36°C for three weeks, five times a week for 20 minutes a day plus magnetotherapy three times weekly.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Magnetotherapy only (control group).
Number of subjects: 63
Study: 20816153

Group type: EXPERIMENTAL
Intervention: Subcuticular 4.0 Monocryl sutures
Number of subjects: 435

Group type: COMPARATOR
Intervention: Stainless steel staples
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Wound complication presence
Number of subjects: 435

Group type: COMPARATOR
Intervention: Comparison of satisfaction between treatment groups
Number of subjects: 435
Study: 18446090

Group type: EXPERIMENTAL
Intervention: High daily dose of soy isoflavones (900 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16181368

Group type: EXPERIMENTAL
Intervention: TACE with doxorubicin (20-60 mg) and lipiodol (2-20 mL)
Number of subjects: 89
Study: 14600448

Group type: EXPERIMENTAL
Intervention: 100 mL nonionic contrast material (300 mgI/mL) pushed with 40 mL saline solution
Number of subjects: 78

Group type: COMPARATOR
Intervention: 120 mL nonionic contrast material (300 mgI/mL) alone
Number of subjects: 78
Study: 10386508

Group type: EXPERIMENTAL
Intervention: Warfarin sodium, 1.25 mg/d
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Warfarin sodium, 1.25 mg/d plus aspirin, 300 mg/d
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg/d
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin therapy aiming at INR of 2.0 to 3.0
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 677

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 677
Study: 8698374

Group type: EXPERIMENTAL
Intervention: Single 1 g oral azithromycin
Number of subjects: 597

Group type: COMPARATOR
Intervention: Doxycycline, 100 mg twice daily for seven days
Number of subjects: 597
Study: 1898642

Group type: EXPERIMENTAL
Intervention: Single-beat analysis method for estimating Ees
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (5 micrograms/kg/min i.v.)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional Ees
Number of subjects: 29
Study: 29282203

Group type: EXPERIMENTAL
Intervention: Behavioral/nutritional modification program to decrease fat and increase vegetable, fruit, and grain intake for an average of 8.1 years
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Behavioral/nutritional modification program
Number of subjects: 48835
Study: 26965499

Group type: EXPERIMENTAL
Intervention: Meeting ACS guidelines for smoking and body weight/physical activity/dietary/alcohol
Number of subjects: 61098

Group type: EXPERIMENTAL
Intervention: Meeting 1 guideline
Number of subjects: 61098

Group type: EXPERIMENTAL
Intervention: Meeting 2 guidelines
Number of subjects: 61098

Group type: EXPERIMENTAL
Intervention: Meeting 3 guidelines
Number of subjects: 61098

Group type: EXPERIMENTAL
Intervention: Meeting 4 guidelines
Number of subjects: 61098

Group type: EXPERIMENTAL
Intervention: Never smokers and non/moderate alcohol drinkers
Number of subjects: 61098

Group type: EXPERIMENTAL
Intervention: Participants without baseline chronic disease
Number of subjects: 61098
Study: 25335326

Group type: EXPERIMENTAL
Intervention: Qizhi Jiangtang Capsule (QJC), 5 pills per time, 3 times a day
Number of subjects: 168

Group type: COMPARATOR
Intervention: Valsartan Capsule 160 mg, once daily
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Qizhi Jiangtang Capsule (QJC)
Number of subjects: 168
Study: 22088966

Group type: EXPERIMENTAL
Intervention: Intervention group (five or more portions of FV per day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (two or fewer portions of FV per day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 20187965

Group type: EXPERIMENTAL
Intervention: Diet and lifestyle intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study: 18596517

Group type: EXPERIMENTAL
Intervention: Antegrade fenestration tubes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Retrograde fenestration tubes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dome fenestration tubes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overall treatment with fenestration tubes
Number of subjects: 25
Study: 15752839

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1521)/AIDSVAX B/E gp120 prime-boost vaccine
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 12052587

Group type: EXPERIMENTAL
Intervention: Endometrial coagulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Endometrial resection
Number of subjects: 120
Study: 10587596

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing sealant applied to 112 teeth after bracket placement.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with 113 teeth that did not receive the fluoride-releasing sealant.
Number of subjects: 20
Study: 8556996

Group type: EXPERIMENTAL
Intervention: 0.6 mg kg‐1 rocuronium in obese patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.6 mg kg‐1 rocuronium in all groups
Number of subjects: 48
Study: 1991925

Group type: EXPERIMENTAL
Intervention: Aztreonam treatment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Skin tests (STs) with aztreonam reagents
Number of subjects: 21

Group type: COMPARATOR
Intervention: Skin tests (STs) with penicilloyl-polylysine (PPL) and penicillin minor determinant mixture
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Serum PPL-specific IgE antibodies
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Serum PPL-specific IgG antibodies
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall tolerance of aztreonam
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Caution with aztreonam
Number of subjects: 21
Study: 6173900

Group type: EXPERIMENTAL
Intervention: Exogenous leukocyte interferon therapy as adjuvant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent control group
Number of subjects: 0
Study: 31836017

Group type: EXPERIMENTAL
Intervention: iHIVARNA-01
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30203668

Group type: EXPERIMENTAL
Intervention: Transitional Care Model
Number of subjects: 202

Group type: COMPARATOR
Intervention: Augmented Standard Care
Number of subjects: 202

Group type: COMPARATOR
Intervention: Resource Nurse Care
Number of subjects: 202
Study: 26977626

Group type: EXPERIMENTAL
Intervention: Mexidol (1000 mg/day for 14-15 days)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no mexidol)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study: 24813928

Group type: EXPERIMENTAL
Intervention: Intervention of antibiotic prescription recommendations evaluated on the third day by an infectious disease specialist.
Number of subjects: 3192

Group type: EXPERIMENTAL
Intervention: Intervention of antibiotic prescription recommendations with dose adjustment or change of route.
Number of subjects: 3192

Group type: EXPERIMENTAL
Intervention: Intervention of antibiotic prescription recommendations that were personally commented on.
Number of subjects: 3192

Group type: EXPERIMENTAL
Intervention: Intervention of antibiotic prescription recommendations overall.
Number of subjects: 3192
Study: 21988468

Group type: EXPERIMENTAL
Intervention: Ceftazidime continuous infusion (4g after 2g loading dose for MDRD 10-30 ml/min, 6g for MDRD 40-80 ml/min, 8g for MDRD 90-110 ml/min, 10g for MDRD 120-190 ml/min, 12g/day for MDRD >200 ml/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime continuous infusion
Number of subjects: 0
Study: 19106729

Group type: EXPERIMENTAL
Intervention: Internet portal-based coaching intervention
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 241
Study: 16236557

Group type: EXPERIMENTAL
Intervention: Experimental group in two-armed trials
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Various reasons for using unequal randomisation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 65
Study: 14558210

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening
Number of subjects: 1173
Study: 10782805

Group type: EXPERIMENTAL
Intervention: Infliximab (5, 10, or 20 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8988539

Group type: EXPERIMENTAL
Intervention: HLA‐A, ‐B, ‐C, ‐DR and ‐DQ phenotypes analysis
Number of subjects: 22854

Group type: EXPERIMENTAL
Intervention: HLA haplotype frequencies analysis
Number of subjects: 22854

Group type: EXPERIMENTAL
Intervention: Phylogenetic tree analysis based on HLA gene frequencies
Number of subjects: 22854

Group type: EXPERIMENTAL
Intervention: Stepwise test for Hardy‐Weinberg equilibrium
Number of subjects: 22854
Study: 1457267

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg as capsules) and soluble paracetamol (1 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg as capsules)
Number of subjects: 8
Study: 6379120

Group type: EXPERIMENTAL
Intervention: Full dosage daunorubicin, cytosine arabinoside, and 6-thioguanine (F DAT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attenuated dosage daunorubicin, cytosine arabinoside, and 6-thioguanine (At DAT)
Number of subjects: 40
Study: 31195056

Group type: EXPERIMENTAL
Intervention: Real tSMS
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MonoAP TMS
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Biphasic TMS
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham tSMS
Number of subjects: 23
Study: 28826968

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 30
Study: 26462677

Group type: EXPERIMENTAL
Intervention: 3D movie
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D movie
Number of subjects: 0
Study: 23821397

Group type: EXPERIMENTAL
Intervention: Noise30 (30 aircraft noise events per night, average SPL 60 dB(A))
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Noise60 (60 aircraft noise events per night, average SPL 60 dB(A))
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no noise)
Number of subjects: 75
Study: 21650084

Group type: EXPERIMENTAL
Intervention: Prasugrel free base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel free base with lansoprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel hydrochloride with lansoprazole
Number of subjects: 0
Study: 18653184

Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg/day, orally)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Intranasal buserelin acetate (900 microg/day, intranasally)
Number of subjects: 271
Study: 17088316

Group type: EXPERIMENTAL
Intervention: Steady-state free precession (SSFP) cardiovascular magnetic resonance
Number of subjects: 120
Study: 15096442

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tracheal intubation (using laryngoscopy or intubating LMA)
Number of subjects: 27
Study: 11497535

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days (n = 45)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Matching placebo (n = 22)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 67

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 67
Study: 9504447

Group type: EXPERIMENTAL
Intervention: Campbell's Center for Nutrition and Wellness plan (CCNW)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Dietary therapy with participant selected diet
Number of subjects: 101
Study: 8040666

Group type: EXPERIMENTAL
Intervention: CT/RT (chemotherapy with radiotherapy)
Number of subjects: 63

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 63
Study: 2568051

Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo irradiation (control)
Number of subjects: 0
Study: 31633440

Group type: EXPERIMENTAL
Intervention: Backward walking at 0° (Group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Backward walking at 5° (Group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Backward walking at 10° (Group C)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Backward walking at 15° (Group D)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no backward walking)
Number of subjects: 52
Study: 28972419

Group type: EXPERIMENTAL
Intervention: Patient-centred team-coaching approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28646887

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA) 4 mg followed by dornase alfa 5 mg, administered once daily for 3 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (tPA 4 mg followed by normal saline), administered once daily for 3 days.
Number of subjects: 0
Study: 26578852

Group type: EXPERIMENTAL
Intervention: Powdered tart cherries [CherryPURE(®)] (TC, n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (P, n = 12)
Number of subjects: 23
Study: 24249853

Group type: EXPERIMENTAL
Intervention: Advanced pharmacy practice experience (APPE) in medication therapy management (MTM)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Other fourth-year students
Number of subjects: 464
Study: 21524808

Group type: EXPERIMENTAL
Intervention: Random practice with every-trial augmented feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked practice with every-trial augmented feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked practice with faded feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random practice with faded feedback
Number of subjects: 0
Study: 19061704

Group type: EXPERIMENTAL
Intervention: Incentive spirometry with expiratory positive airway pressure (IS+EPAP)
Number of subjects: 34
Study: 17333792

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg, once daily for 5 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metronidazole (250 mg, 3 times a day for 5 days)
Number of subjects: 120
Study: 12721685

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Meta-analyses
Number of subjects: 671
Study: 11566458

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg orally every 12 hours for 5 days)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 9036746

Group type: EXPERIMENTAL
Intervention: Standard-dose heparin (100 U/kg bolus)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (70 U/kg bolus)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Early sheath removal (heparin stopped after procedure)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combination of low-dose heparin and early sheath removal
Number of subjects: 103

Group type: COMPARATOR
Intervention: Late sheath removal (heparin continued for 12 hours)
Number of subjects: 103
Study: 8342759

Group type: EXPERIMENTAL
Intervention: Fixed CPB flow of 2.4 l.m-2
Number of subjects: 122

Group type: COMPARATOR
Intervention: Tailored bypass flow to maintain venous return oxygen saturation of 75-80%
Number of subjects: 122
Study: 3296129

Group type: EXPERIMENTAL
Intervention: Oral thromboxane synthetase inhibitor (TSI)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31353458

Group type: EXPERIMENTAL
Intervention: Inquiry-based learning approach with reflections on epistemic issues (intervention)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 30392388

Group type: EXPERIMENTAL
Intervention: Exercise group (4-month concurrent training, 3 days/week, 60 min/session)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Counseling group
Number of subjects: 150
Study: 26621631

Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB-12 added post-fermentation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB-12 added (any form)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BB-12 (in any form)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Yogurt smoothie alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BB-12 given in capsule form
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB-12 added before fermentation
Number of subjects: 30
Study: 24073964

Group type: EXPERIMENTAL
Intervention: Carotenoid-rich dietary pattern (CDP)
Number of subjects: 2983
Study: 22075942

Group type: EXPERIMENTAL
Intervention: 150 mg DIM daily for 6 months
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo daily for 6 months
Number of subjects: 551
Study: 20817384

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 361

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 361
Study: 17621671

Group type: EXPERIMENTAL
Intervention: Reduced-dose sirolimus-eluting stents (SESs)
Number of subjects: 44
Study: 15765241

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham training (placebo)
Number of subjects: 12
Study: 11982448

Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Olanzapine 5.0 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Olanzapine 7.5 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Olanzapine 10.0 mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Haloperidol 7.5 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 270
Study: 10596656

Group type: EXPERIMENTAL
Intervention: Electronic Dental Anesthesia (EDA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical anesthetic ointment of Xylocaine 5%
Number of subjects: 30
Study: 15714749

Group type: EXPERIMENTAL
Intervention: Co-administration of anticoagulants with antiplatelet agents with rheological effects (piracetam, buflomedil, pentoxifylline)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Co-administration of anticoagulants with dipyridamole (antiplatelet agent without rheological effects)
Number of subjects: 600
Study: 2065391

Group type: EXPERIMENTAL
Intervention: JWYY tablets
Number of subjects: 494

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 494
Study: 675836

Group type: EXPERIMENTAL
Intervention: Topical diethylcarbamazine citrate (DEC) applied daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly topical applications of DEC emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral administration of diethylcarbamazine citrate (DEC)
Number of subjects: 0
Study: 31818845

Group type: EXPERIMENTAL
Intervention: Intraperitoneal irinotecan added to standard systemic therapy (5-fluorouracil/leucovorin with oxaliplatin and bevacizumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard systemic therapy (5-fluorouracil/leucovorin with oxaliplatin and bevacizumab)
Number of subjects: 0
Study: 28994364

Group type: EXPERIMENTAL
Intervention: Sildenafil (1-3 mg/kg/day every 8 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tadalafil (1 mg/kg once a day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both sildenafil and tadalafil
Number of subjects: 42
Study: 26125945

Group type: EXPERIMENTAL
Intervention: Orally administered trimethoprim-sulfamethoxazole (TSM)
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Intravenously administered cefuroxime and metronidazole (CXM)
Number of subjects: 1073
Study: 21357655

Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Twin Block appliance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22093308

Group type: EXPERIMENTAL
Intervention: Tracheal detecting bulb (TDB) during endotracheal intubation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (without TDB) during endotracheal intubation
Number of subjects: 62
Study: 19860906

Group type: EXPERIMENTAL
Intervention: Mailed letters of invitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advertisement in health plan's magazine
Number of subjects: 0
Study: 16900802

Group type: EXPERIMENTAL
Intervention: 30 mg of prednisone daily for 5 consecutive days before the operation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 36
Study: 16787139

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 0
Study: 12900342

Group type: EXPERIMENTAL
Intervention: TAAA repair patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MBL-deficient TAAA patient
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MBL-sufficient TAAA patients
Number of subjects: 19
Study: 10051860

Group type: EXPERIMENTAL
Intervention: Use of a walker
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Use of assistive devices (cane or walker)
Number of subjects: 1212
Study: 7729788

Group type: EXPERIMENTAL
Intervention: 4 mg of oral DEX
Number of subjects: 6
Study: 2040714

Group type: EXPERIMENTAL
Intervention: Desipramine (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7041450

Group type: EXPERIMENTAL
Intervention: Extra-amniotic prostaglandin E2 gel
Number of subjects: 143

Group type: COMPARATOR
Intervention: Amniotomy with or without intravenous oxytocin
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Extra-amniotic PGE2 gel plus an indwelling catheter
Number of subjects: 143
Study: 31030879

Group type: EXPERIMENTAL
Intervention: Mindfulness training (15-minute duration)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no-instruction, relaxing music)
Number of subjects: 107